Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations

BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations

路透社路透社2026/11/09 22:31
Show original

- ** As a smaller peer of SpaceX SPCX.O, Rocket Lab RKLB.O's share price fell 3% in after-hours trading, closing at $57.08

** Despite strong revenue growth, investors remain cautious, mainly due to concerns about the company's profitability

** According to data compiled by LSEG, the company reported a loss of 12 cents per share for the three months ended September 30, while analysts had previously expected a loss of 7 cents per share

** Last month, RKLB postponed the maiden flight of its new large "Neutron" rocket until next year. The company had previously planned the "Neutron" rocket's first launch for the fourth quarter of 2026

** The company reported third-quarter revenue of $267.8 million, up from $115.1 million in the same period last year

** Fourth quarter revenue is expected to be between $270 million and $290 million, while analysts expect $265.4 million

** The company expects an adjusted EBITDA loss of between $14 million and $20 million for the fourth quarter

** As of the close of the previous trading day, the share price of this company, with a market capitalization of $31.76 billion, has fallen 15.62% so far this year


(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or omit important context, Reuters does not guarantee the accuracy of translated texts. Automated translations are provided solely for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation functions.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12